Show simple item record

dc.contributor.authorChen, Clark C
dc.contributor.authorKennedy, Richard D
dc.contributor.authorSidi, Samuel
dc.contributor.authorLook, A. Thomas
dc.contributor.authorD'Andrea, Alan David
dc.date.accessioned2012-01-08T23:49:36Z
dc.date.issued2009
dc.identifier.citationChen, Clark C, Richard D Kennedy, Samuel Sidi, A Thomas Look, and Alan D'Andrea. 2009. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Molecular Cancer 8: 24.en_US
dc.identifier.issn1476-4598en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:7349721
dc.description.abstractBackground: DNA repair deficient tumor cells have been shown to accumulate high levels of DNA damage. Consequently, these cells become hyper-dependent on DNA damage response pathways, including the CHK1-kinase-mediated response. These observations suggest that DNA repair deficient tumors should exhibit increased sensitivity to CHK1 inhibition. Here we offer experimental evidence in support of this hypothesis. Results: Using isogenic pairs of cell lines differing only in the Fanconi Anemia (FA) DNA repair pathway, we showed that FA deficient cell lines were hypersensitive to CHK1 silencing by independent siRNAs as well as CHK1 pharmacologic inhibition by Gö6976 and UCN-01. In parallel, an siRNA screen designed to identify gene silencings synthetically lethal with CHK1 inhibition identified genes required for FA pathway function. To confirm these findings in vivo, we demonstrated that whole zebrafish embryos, depleted for FANCD2 by a morpholino approach, were hypersensitive to Gö6976. Silencing of FA genes led to hyper-activation of CHK1 and vice versa. Furthermore, inactivation of CHK1 in FA deficient cell lines caused increased accumulation of DNA strand and chromosomal breakages. These results suggest that the functions subserved by CHK1 and the FA pathway mutually compensate in maintaining genome integrity. As CHK1 inhibition has been under clinical trial in combination with cisplatin, we showed that the FA specific tumoricidal effect of CHK1 inhibition and cisplatin was synergistic. Conclusion: Taken together, these results suggest CHK1 inhibition as a strategy for targeting FA deficient tumors.en_US
dc.language.isoen_USen_US
dc.publisherBioMed Centralen_US
dc.relation.isversionofdoi://10.1186/1476-4598-8-24en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2672921/pdf/en_US
dash.licenseLAA
dc.titleCHK1 Inhibition as a Strategy for Targeting Fanconi Anemia (FA) DNA Repair Pathway Deficient Tumorsen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalMolecular Canceren_US
dash.depositing.authorLook, A. Thomas
dc.date.available2012-01-08T23:49:36Z
dash.affiliation.otherHMS^Surgery- Beth Israel-Deaconessen_US
dash.affiliation.otherSPH^Genetics and Complex Diseasesen_US
dash.affiliation.otherHMS^Radiation Oncology-BWH-DFCI-CHen_US
dash.affiliation.otherHMS^Pediatrics-Children's Hospitalen_US
dc.identifier.doi10.1186/1476-4598-8-24*
dash.contributor.affiliatedLook, A.
dash.contributor.affiliatedD'Andrea, Alan


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record